

Summary of Oncopole's accreditations, certifications and labels

Haute Autorité de Santé (French National Health Authority) certification



Oncopole Claudius Regaud (OCR)



Toulouse University Hospital (CHU)

The French hospital accreditation programme has been established in law since 1996. It aims to improve quality and patient safety through sustainable changes in clinical practice and hospital management. HAS standards assess hospital performance and define requirements ensuring safe patient care.

In November 2024, Oncopole Claudius Regaud obtained the highest distinction, High Quality of Care, without recommendations, for a further four-year period.

Toulouse University Hospital was certified in May 2024 for four years.

Organisation of European Cancer Institutes (OECI)



The OECI was established in 1979 to promote greater cooperation between European cancer centres and institutes. Its mission is to improve access to care and to develop cancer education and research. Through an accreditation process, it awards a mark of excellence to the most recognised institutions in Europe.

The Oncopole and the Toulouse Cancer Research Centre (CRCT) were accredited as **Comprehensive Cancer Centres (CCC)** in 2019 by the OECI. At the same time, Toulouse's public cancer centres were awarded the **OECI Network** label in 2021.

According to the report, the Oncopole offers a modern and supportive environment for patients, medical teams and researchers.

The Oncopole has a clear and coherent strategy, with strong integration between the public and private sectors and no duplication in the various forms of care provided. Research is a major strength, particularly thanks to its strong translational focus and close links with clinical practice. The infrastructure is modern and well-equipped, and innovation is actively encouraged. The radiotherapy department stands out as an excellent example of integration between care, research and innovation. Other key strengths identified during the visit include:

- a pharmacy with high standards of quality and safety and a robust organisational structure
- a highly developed supportive care department, unique in Europe, offering holistic patient care
- a well-structured biobank capable of meeting the needs of translational research
- a high level of patient satisfaction.

The visit also highlighted the following opportunities for improvement:

- Continue the deployment of the new strategic plan following the appointment of the new Chief Executive
- Develop clinical indicator dashboards to continue improving the quality of care and support translational research
- Strengthen translational research through international collaborations
- Continue to develop links with innovative companies in the region
- Strengthen diagnostic radiology care capacity
- Continue to develop specific training programmes in oncology
- Set up a coordination unit for unexpected admissions
- Develop patient partnerships and post-cancer care

HCERES



The Toulouse Cancer Research Centre (CRCT) has been accredited by the committee of the High Council for the Evaluation of Research and Higher Education (HCERES). This independent public authority is responsible for evaluating higher education and research institutions, national research organisations, research units and training programmes.

The committee highlights the exceptional quality of the scientific work carried out at the CRCT. It also emphasises the unit's capacity for innovation, its appeal, its international profile, and its ability to fund and implement its scientific strategy. Furthermore, it notes the excellent integration of its research activities into clinical care, particularly through clinical trials and the creation of databases useful for research.

OCR and CHU Clinical Research Units



The two clinical research units located on the Oncopole are certified to ISO 9001:2015 by AFNOR. Certification is renewed annually.

CLIP2 label for early-phase clinical trials



CLIP² centres are specialist research centres, particularly within healthcare institutions, dedicated to early-phase trials of new medicines developed by pharmaceutical companies, biotechnology firms and academic research laboratories.

The centre has been awarded the CLIPP (Early-Phase Clinical Trial Centres in Adult and Paediatric Oncology) accreditation by INCa for the next five years (2024–2029). This mark of excellence recognises expertise in oncology and highlights the multidisciplinary nature of patient care, as well as the high level of interaction between clinical practice and research.

Qualiopi certification for training



Qualiopi is a quality label for training providers, awarded by certification bodies accredited or approved by the French Accreditation Committee (Cofrac) on the basis of the national quality framework.

OCR Training Centre

This certification was last renewed in December 2024 and is valid for a period of three years. It identified only a few areas for improvement, relating in particular to the procedures for dealing with difficulties encountered by stakeholders during the delivery of services and formalities with subcontractors.

University Hospital Training Centre

The certification was renewed in December 2024 for a further three years, with no recommendations.

Pharmacy



The in-house pharmacy (PUI) at the IUCT-Oncopole is certified to the ISO 9001:2015 standard; the most recent renewal took place in June 2025.

Radiology

Nuclear Safety and Radiation protection Agency (ASNR) inspections



The Brachytherapy Unit was inspected in 2024 in accordance with standard INSNP-BDX-2024-0001.

The Interventional Radiology Unit was inspected in 2021 in accordance with standard INSNP-BDX-2021-0899.

No critical issues were identified.

Nuclear Medicine

Nuclear Safety and Radiation protection Agency (ASNR) inspections



The Nuclear Medicine departments were inspected in 2025 in accordance with standard INSNP-BDX-2024-0005.

No critical issues were identified.

EANM (European Association of Nuclear Medicine)



The EARL accreditations (which validate the level of excellence in the care provided in nuclear medicine) have been renewed for PET and FDG, as well as the Level 1 EARL Theranostics accreditation.

ENETS (European Neuroendocrine Tumour Society)



Accreditation by this organisation was renewed in May 2025. The annual data for 2025 provide an excellent overview of the well-established structure of the ENETS Centre of Excellence, its multidisciplinary team activities and all the key indicators required.

Radiotherapy

Nuclear Safety and Radiation protection Agency (ASNR) inspections



The most recent inspection of the Radiotherapy Department took place in February 2025 in accordance with standard INSNP-BDX-2025-0110.

No critical issues were identified.

Novalis certification obtained in July 2022 for a period of four years



This certification promotes the independent external assessment of specialised procedures and workflows, as well as the collaborative approach required for high-precision radiation oncology treatments. It is awarded following a rigorous on-site and remote assessment process, focusing on procedures and protocols that emphasise continuous self-assessment and quality improvement. It also helps centres assess their current practices against those of other centres of excellence through a confidential review of the programme and discussions that suggest improvements and identify key areas for refining and implementing procedures.

Pathology



Onco-haematology Laboratory

The accreditation of the 'Toulouse University Hospital Clinical Chemistry Laboratory' – Onco-haematology section – in accordance with ISO 15189:2022 was renewed in 2026.

Medical biology Laboratory

The most recent surveillance visit took place in 2025, in accordance with ISO 15189:2022.

Cell therapy Unit



JACIE (Joint Accreditation Committee ISTC-EBMT) Accreditation

An inspection took place in 2019 and the Accreditation Committee commended the staff's commitment to the JACIE process, which resulted in a high-quality initial inspection report. It was noted that there were no activities relating to CAR-T cells; however, if this were to change, consideration would need to be given to including this aspect of the service in the inspection.

The next accreditation visit took place in April 2026, including CAR-T cells.

Biological Resources Centre (CRB) Certification



The CRB laboratory is certified as compliant with the ISO 9001:2015 and ISO 20387:2018 standards.

The report confirms that the CRB has a robust, compliant and effective management system that fully meets the requirements of the ISO 9001 and 20387 standards. Processes are well-controlled and the organisation is mature and well-structured. The CSR approach, and the culture of quality and safety, are key strengths.

Several areas for improvement were highlighted:

- the growing pressure on resources linked to the significant increase in non-conformities in 2024 (due to increased activity and ageing equipment)
- the lack of storage capacity (tanks, -80°C), a critical issue for a CRB that could limit its ability to accept new collections
- the visibility of the CRB, identified as insufficient despite communication efforts
- the DPI-Tumorotek IT link, which still has room for improvement and may hinder the smooth flow of traceability